Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)

Leukemia & Lymphoma
Morie A GertzPhilip R Greipp

Abstract

Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.

References

Dec 2, 2000·Annals of Hematology·R Thalhammer-ScherrerU Jäger
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos
Jun 5, 2002·Cytotherapy·J M Vose
Aug 7, 2002·Blood Reviews·S A JohnsonV Leblond
Jan 11, 2003·Clinical Lymphoma·Meletios A DimopoulosJohn Christakis
Apr 25, 2003·Anti-cancer Drugs·Andre BoslyKen Bradstock
Apr 30, 2003·Seminars in Oncology·Christos Emmanouilides

❮ Previous
Next ❯

Citations

Jul 20, 2007·Current Treatment Options in Oncology·Meletios A Dimopoulos, Athanasios Anagnostopoulos
Jun 19, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Lucy S Hodge, Stephen M Ansell
Aug 30, 2011·Bone Marrow Transplantation·M A GertzS M Ansell
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Aug 21, 2008·Blood·Steven P TreonKenneth C Anderson
Jul 21, 2009·Blood·Steven P Treon
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonIrene M Ghobrial
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialThomas E Witzig
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialJeffrey Matous
Oct 29, 2011·Clinical Investigation·Ghayas C IssaAldo M Roccaro
Apr 26, 2014·Immunotherapy·Laetitia Souchet-CömpainStéphanie Nguyen
Sep 13, 2014·Hematology/oncology Clinics of North America·Steven P TreonGiampaolo Merlini
Aug 27, 2009·Biologics : Targets & Therapy·Beate Hauptrock, Georg Hess
Aug 7, 2012·Leukemia & Lymphoma·Morie Gertz
Apr 6, 2012·Expert Review of Hematology·Pierre Morel, Giampaolo Merlini
Sep 11, 2010·Expert Opinion on Emerging Drugs·Jack D Burton, David M Goldenberg
Sep 4, 2008·Clinical Lymphoma & Myeloma·Arun Vijay, Morie A Gertz
Feb 21, 2006·British Journal of Haematology·S A JohnsonUNKNOWN Haemato-Oncology Task Force of the British Committee for Standards in Haematology
Mar 6, 2008·British Journal of Haematology·Prashant KapoorPhilip R Greipp
May 9, 2013·British Journal of Haematology·Anita D'SouzaMorie A Gertz
May 24, 2015·Blood·Steven P Treon
Apr 18, 2015·Blood Reviews·Prashant KapoorPhilip R Greipp
Mar 31, 2015·Blood Cancer Journal·A Oza, S V Rajkumar
Jul 16, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Jonathan J Hogan, Brendan M Weiss
Jun 1, 2007·Journal of the Neurological Sciences·Michelle L MauermannChristopher J Klein
Jan 4, 2017·Expert Opinion on Investigational Drugs·Maria GavriatopoulouMeletios A Dimopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Steven P TreonWaldenström's Macroglobulinemia Clinical Trials Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M DimopoulosNikolaos Anagnostopoulos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M DimopoulosGerasimos Pangalis
© 2021 Meta ULC. All rights reserved